Inflammatory Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Inflammatory Breast Cancer Market Outlook

Thelansis’s “Inflammatory Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Inflammatory Breast Cancer Overview

Inflammatory breast cancer is a rapidly progressing and aggressive form of breast cancer characterized by the infiltration of cancer cells into the skin and lymph vessels of the breast. Unlike many other breast cancers, it often lacks a distinct tumor or lump that can be palpated within the breast. Early symptoms of inflammatory breast cancer may manifest as persistent itching and a rash or small irritation resembling an insect bite. The affected breast typically becomes red, swollen, and warm, accompanied by the dilation of pores on the breast skin, which can give it a pitted appearance similar to an orange peel. Additionally, changes in the nipple, such as inversion, flattening, or dimpling, may occur. There are several established risk factors associated with inflammatory breast cancer. Reproductive factors play a significant role, with a higher risk observed in women who experience early menarche and give birth to their first child at a younger age. Inflammatory breast cancer is categorized into either stage 3B, 3C, or stage 4, each with distinct characteristics:

• Stage 3B involves the spread of cancer into nearby tissues, such as the skin of the breast and the underlying chest muscle, potentially extending to lymph nodes in the armpit.
• Stage 3C signifies the presence of cancer in lymph nodes located in the armpit or below the breastbone, either above or below the collarbone.
• Stage 4 indicates that the cancer has extended beyond the breast and nearby lymph nodes.

The minimum criteria for diagnosing inflammatory breast cancer include the following:

1. The rapid onset of symptoms, including redness (erythema), swelling (edema), a peau d'orange texture (ridged or pitted skin), and abnormal warmth in the breast, with or without a palpable lump.
2. The symptoms have been present for less than six months.
3. The redness (erythema) affects at least one-third of the breast.
4. Initial biopsy samples from the affected breast confirm the presence of invasive carcinoma.

Treatment for inflammatory breast cancer typically includes surgery, radiation therapy, chemotherapy, and hormone treatments.

• In the United States, there are an estimated 3.1 cases of inflammatory breast cancer per 100,000 women, which is more commonly diagnosed in women under 40.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: